Business Context and Reporting Period
This Form 8-K reports on the 2022 Annual Meeting of Stockholders for Alnylam Pharmaceuticals, Inc., held on May 18, 2022. The report details the voting outcomes for director elections, stock plan amendments, executive compensation, and auditor ratification.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on corporate governance and shareholder voting results.
Material Changes and Voting Results
As of the record date (March 28, 2022), 120,718,462 shares of common stock were issued and outstanding. The following matters were voted upon:
- Director Elections (Class III): Stockholders re-elected Margaret A. Hamburg, M.D., Colleen F. Reitan, and Amy W. Schulman to serve until the 2025 annual meeting. All three candidates received majority support, though Amy W. Schulman received a higher number of "Against" votes (3,856,744) compared to the other two candidates.
- Stock Incentive Plan: Stockholders approved the Amendment and Restatement of the 2018 Stock Incentive Plan. Approximately 12.4 million votes were cast against the proposal.
- Executive Compensation: In a non-binding advisory vote, stockholders approved the compensation of named executive officers. Approximately 10.5 million votes were cast against the proposal.
- Auditor Ratification: Stockholders ratified the appointment of PricewaterhouseCoopers LLP as independent auditors for the fiscal year ending December 31, 2022, with overwhelming support (over 109 million votes for).
Guidance, Outlook, and Risks
The filing text does not provide management commentary, financial guidance, outlook, or specific risk factors. It is a procedural report of shareholder meeting results.
Key Facts for Investor Verification
- Verify the specific terms of the approved Amendment and Restatement of the 2018 Stock Incentive Plan to understand potential dilution impacts.
- Note the significant number of "Against" votes for the executive compensation advisory vote (approx. 10.5 million) and the Stock Incentive Plan amendment (approx. 12.4 million), which may indicate shareholder sentiment regarding capital allocation or pay structures.
- Confirm the continued tenure of the remaining directors (Class I and II) who were not up for election at this meeting.